Exagen Inc.

NASDAQ:XGN

Medical - Diagnostics & Research

Healthcare
$3.90 +3.84%

+$0.16 today

Market cap
$99.50M
Beta
2.02
P/E (TTM)
-5.2
EPS (TTM)
-$0.85
52W Low $2.59High $12.23

Volume 0.47M

Average 0.39M

XGN Net Income

Bottom-line profit after all expenses, interest, and taxes.

Exagen Inc.NASDAQ: XGN

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$3.97M, compared with -$3.75M a year earlier. Trailing-twelve-month net income was -$20.17M.

Context

  • Net income amounted to 30.0% of revenue in FY2025, up 2.8 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 6 analysts of -$15.58M (+21.9%) for the fiscal year ending Dec 2026, a step up from the -32.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.97M+15.1% QoQ
Last fiscal yearDec 2025
-$19.95M-32.0% YoY
LTMMar 2026
-$20.17M-30.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.7%-7.2%-1.4 pp
1 year-32.0%+21.9%+53.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(19.95M) USD
Year-over-year change
-32.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How XGN compares with its peers on the latest reported figures

  • XGN's LTM Mar 2026 net income of -$20.17M is the 2nd highest of the 11 companies compared; the peer median is -$35.67M.
  • Its year-over-year change of -30.0% is the 8th highest of 10, against a peer median of +14.5%.
  • Net income amounts to 29.5% of revenue for XGN, versus a peer median of 43.9%.
XGN Competitors Peer median
Net Income for XGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TKNOAlpha Teknova, Inc.LTM Mar 2026-$17.17M +26.3%—41.1%
XGNExagen Inc.LTM Mar 2026-$20.17M -30.0%—29.5%
STXSStereotaxis, Inc.LTM Mar 2026-$21.68M +14.5%—69.5%
MDXHMDxHealth S.A.FY2025-$33.52M +12.0%—31.1%
SMTISanara MedTech Inc.LTM Mar 2026-$33.58M -193.9%—31.2%
LFCRLifecore Biomedical, Inc.LTM Mar 2026-$34.09M ——25.2%
SGHTSight Sciences, Inc.LTM Mar 2026-$37.25M +24.6%—46.8%
NEONeoGenomics, Inc.LTM Jun 2026-$51.88M +50.1%—6.8%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$69.66M +46.5%—832.6%
BIOABioAge Labs, Inc.LTM Mar 2026-$89.93M -26.6%—871.8%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026-$239.55M -441.4%—110.0%
Peer median (excluding XGN) -$35.67M+14.5%—43.9%

Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.3M45.56M52.55M55.64M66.58M
Cost of Revenue20.59M24.21M23.09M22.53M27.78M
Gross Profit27.71M21.35M29.46M33.11M38.8M
Gross Margin57.4%46.9%56.1%59.5%58.3%
Research & Development7.24M9.88M4.87M5.38M6.25M
Selling, General & Admin44.54M52.02M47.43M41.37M46.62M
Operating Expenses51.78M67.4M52.29M46.75M52.87M
Depreciation & Amortization948K1.56M2.17M1.72M2.12M
EBITDA(23.1M)(43.66M)(19.15M)(11.15M)(13.46M)
EBITDA Margin-47.8%-95.8%-36.4%-20.0%-20.2%
Operating Income(24.07M)(46.05M)(22.84M)(13.64M)(14.07M)
Operating Margin-49.8%-101.1%-43.5%-24.5%-21.1%
Interest Income16K830K1.52M767K289K
Interest Expense2.63M2.45M2.34M2.23M4.32M
Other Income / Expenses(2.61M)(1.62M)(819K)(1.47M)(5.83M)
Income Before Tax(26.68M)(47.67M)(23.66M)(15.1M)(19.9M)
Pre-Tax Margin-55.2%-104.6%-45.0%-27.1%-29.9%
Income Tax Expense175K(282K)33K12K51K
Net Income(26.85M)(47.39M)(23.69M)(15.12M)(19.95M)
Net Margin-55.6%-104.0%-45.1%-27.2%-30.0%
EPS (Basic)(1.68)(2.77)(1.34)(0.83)(0.93)
EPS (Diluted)(1.68)(2.77)(1.34)(0.83)(0.93)
Weighted Avg Shares15.97M17.08M17.68M18.2M21.56M
Weighted Avg Shares (Diluted)15.97M17.08M17.68M18.2M21.56M

Exagen Inc.

NASDAQ:XGN

Intrinsic Alpha fair value

Locked

Current Price

$3.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.